Caribou Biosciences
David Beyer is a seasoned investor and partner at Amplify Partners, providing strategic guidance since November 2013. Currently serving as an investor for multiple companies, including tldraw, Luma AI, Foxglove, Airtable, Cruise Automation, Caribou Biosciences, Hightouch, Astranis, and Casetext. Notably, David is involved with early-stage investments as evidenced by the role at Casetext. David Beyer earned a Bachelor of Arts degree from Brown University between 2004 and 2008 and attended Phillips Academy Andover from 2000 to 2003.
This person is not in any teams
This person is not in any offices
Caribou Biosciences
2 followers
Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR biology and located in Berkeley, CA. The company is developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.